Clinical trials: Congestive Heart Failure Chronic

Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

• Completed
• Age: 18 years and older
• Phase 3
• Results posted

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF).

Trial name

VICTORIA (NCT02861534)

Testing

Vericiguat

Volunteers

5,050 people

Sponsor

Merck Sharp & Dohme LLC